POPULARITY
32 episodes with xalkori
34 episodes with xalkori
4 episodes with xalkori
Dr Patil emphasized the significance of the phase 3 CROWN trial (NCT03052608), which compared lorlatinib (Lorbrena) with crizotinib (Xalkori) in patients with ALK-positive metastatic NSCLC. With a hazard ratio of 0.19 (95% CI, 0.13-0.27) for progression-free survival, the trial demonstrated lorlatinib's superior intracranial control and long-term efficacy compared with crizotinib, especially in patients with brain metastases. Drs Park and Patil also discussed challenges associated with managing lorlatinib-related toxicities, including mood changes, weight gain, and hyperlipidemia. Dr Patil suggested that starting at a lower dose and gradually escalating to the recommended dose could help mitigate some of these adverse effects and simultaneously maintain treatment efficacy. The conversation concluded with a shift towards the broader application of targeted therapies in earlier disease stages, drawing parallels between the phase 3 ALINA study (NCT03456076) in patients with ALK-positive
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
Listen to a soundcast of the July 14, 2022 FDA approval of Xalkori (crizotinib) for ALK-positive inflammatory myofibroblastic tumor.
“To be a scientist,” notes Steve Morris, MD, “you have to take failure after failure with undying enthusiasm.” Without that persistence, we might never have had the lung cancer drug Crizotinib. The path to that drug’s development spanned more than two decades, and Dr. Morris played a critical and recurring role. In 1994, Dr. Morris and his team discovered the gene ALK and showed that it plays a critical role in some lymphomas. He went on to help show that a variety of cancer sub-types are caused by ALK abnormalities, including certain lung cancers, lymphomas, leukemias, mesotheliomas, thyroid cancers, and pediatric cancers. But he didn’t stop with discovery. He and his team also created a diagnostic test, the Vysis ALK Break Apart FISH Probe Kit, to help clinicians determine if a patient’s tumors have an abnormal ALK gene. Ultimately his efforts helped drug developers to come up with the lung cancer drug Xalkori (crizotinib), which was first approved by the FDA in 2011 for the treatment of ALK-positive non-small cell lung cancer. The drug’s use has been expanded since. Crizotinib is also being evaluated as a potential targeted drug therapy in the treatment of neuroblastoma, a type of brain cancer, and other cancers with ALK mutations or rearrangements. Up to 15% of neuroblastomas have mutations in the ALK gene. Steve Morris, MD, is the co-founder of Insight Genetics and serves as Chief Medical Officer for companies developing cancer therapies. Prior to that he was a Full Member at St. Jude Children’s Research Hospital. 4:49 – On his team’s “time-consuming, labor-intensive, capital-intensive” discovery of the ALK gene 8:48 – How ALK plays a role in cancer 11:20 – The road to making ALK a druggable target 16:58 – The diagnostic test he and his team developed to help clinicians determine if a patient’s tumors have an abnormal ALK gene 26:19 – On why he left academic medicine to pursue drug development and the creation of diagnostic tests 29:32 – On the challenges of drug development, including the low success rate, the long development timeline, and the very high capital investment 32:52 – On the exciting prospects of precision medicine 38:39 – The role of American Cancer Society funding on his career and the discovery of ALK
GRACE is happy to present the 5th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the J-Alex trial and whether Alecensa should replace Xalkori as First-Line ALK Therapy.
GRACE is happy to present the 5th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the J-Alex trial and whether Alecensa should replace Xalkori as First-Line ALK Therapy.
GRACE is happy to present the 5th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the J-Alex trial and whether Alecensa should replace Xalkori as First-Line ALK Therapy.
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.
Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.
Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.
Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.
Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.
Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.
Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
ROS1 lung cancer patient Lisa Goldman credits research with keeping her alive. November is Lung Cancer Awareness Month. What are you grateful for?
ROS1 lung cancer patient Lisa Goldman credits research with keeping her alive. November is Lung Cancer Awareness Month. What are you grateful for?
ROS1 lung cancer patient Lisa Goldman credits research with keeping her alive. November is Lung Cancer Awareness Month. What are you grateful for?
November is Lung Cancer Awareness Month. To mark it this year, GRACE is celebrating the empowered lung cancer patient. In this video, Linnea Duff, a 10-year stage IV ALK+ lung cancer patient, shares her journey from stunned patient to empowered patient.
November is Lung Cancer Awareness Month. To mark it this year, GRACE is celebrating the empowered lung cancer patient. In this video, Linnea Duff, a 10-year stage IV ALK+ lung cancer patient, shares her journey from stunned patient to empowered patient.
November is Lung Cancer Awareness Month. To mark it this year, GRACE is celebrating the empowered lung cancer patient. In this video, Linnea Duff, a 10-year stage IV ALK+ lung cancer patient, shares her journey from stunned patient to empowered patient.
Acquired Resistance Forum Video #14: Speakers from video #11 and video #12 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.
Acquired Resistance Forum Video #14: Speakers from video #11 and video #12 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.
Acquired Resistance Forum Video #14: Speakers from video #11 and video #12 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.
Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.
Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.
Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.
Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.
Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.
Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.
Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.
Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.
Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.
Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014
Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014
Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014
For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014
For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014
For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.
Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.
Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.
© 2020-2025 Ivy Podcast Discovery LLC
